The diabetes medication exenatide did not slow motor symptom progression in treated Parkinson’s patients relative to those given a placebo, failing at the main goal of a Phase 3 study. Exenatide — sold in the U.S. under brand names including Byetta and Bydureon BCise, and used to help…
News
The average caregiver for someone with Parkinson’s disease spends more than 30 hours per week doing unpaid work to provide care, and many report substantial emotional and physical strain. That’s according to a new report from the National Alliance for Caregiving (NAC), with support from…
Cyrano Therapeutics is supporting an investigator-initiated clinical study that will evaluate CYR-064, its leading nasal candidate therapy, to restore smell loss in Parkinson’s disease. The study, led by neurologist David Silvers, MD, in Palm Beach Gardens in Florida, seeks to enroll 15 to 20 adults, ages 18-80, with…
The Parkinson’s Foundation hosted a series of events last year that aimed to recognize the unique needs and experiences of Black and African American people with Parkinson’s disease and empower these patients to participate in research. As part of an initiative called Parkinson’s Journey in Color: Advancing Research…
The U.S. Department of Defense has granted $4 million in funding to support an investigation by U.S. researchers into the underlying factors contributing to the increased risk of Parkinson’s disease in people who experience sleep disturbances and post-traumatic stress disorder, known as PTSD. The focus for the researchers is…
As people age, the immune system ages with them, becoming more sluggish and ineffective — a change that could contribute to Parkinson’s disease, Rebecca Wallings, a 2024 Parkinson’s Foundation Launch Award grant recipient, suggests. “As you age … your immune cells can become exhausted … slow, sluggish, and…
A study found a link between the likely presence of REM sleep behavior disorder (RBD) in people with Parkinson’s disease and greater frequency and severity of other nonmotor symptoms (NMS) that characterize the neurodegenerative disease. The researchers said the results link RBD to a Parkinson’s subtype called…
Despite an accuracy rate of 91% in diagnosing Parkinson’s disease, misdiagnoses still occur in the clinic, particularly with Lewy body dementia being mistaken for Parkinson’s — the two share some symptoms — or people with Parkinson’s being incorrectly told they have Alzheimer’s disease, researchers report. “The findings of…
The U.S. Food and Drug Administration (FDA) has approved Onapgo (apomorphine hydrochloride) for the continuous treatment of motor fluctuations in adults with advanced Parkinson’s disease, making it the first subcutaneous, or under-the-skin, apomorphine infusion device approved for this indication. The application from Supernus Pharmaceuticals was the developer’s fourth…
Jupiter Neurosciences said it’s planning a Phase 2a clinical trial to test Jotrol, the company’s oral formulation of resveratrol, as a treatment for Parkinson’s disease, in partnership with Zina Biopharmaceuticals. Zina will assist with aspects of the trial protocol, such as identifying biomarkers and selecting sites for the…
Recent Posts
- Deep brain stimulation was a lifesaver for my husband with Parkinson’s
- Me and Mary Jane: My one experience trying marijuana for Parkinson’s
- Low muscle mass is more common in early-stage Parkinson’s disease
- Guest Voice: What de facto parenting can teach us about Parkinson’s
- Parkinson’s advocates urge implementation of new federal plan